Edwards Lifesciences (EW) Depreciation & Amortization (CF) (2009 - 2026)

Edwards Lifesciences has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $42.7 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 12.07% year-over-year to $42.7 million in Q2 2026; TTM through Jun 2026 was $165.5 million, a 9.03% increase from a year earlier, with the FY2025 full-year figure at $156.6 million, up 0.9% from the prior year.
• Depreciation & Amortization (CF) was $42.7 million for Q2 2026 at Edwards Lifesciences, up from $40.9 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $42.7 million in Q4 2025, with the low at $34.1 million in Q2 2022.
• Average Depreciation & Amortization (CF) over 5 years is $37.8 million, with a median of $36.8 million recorded in 2023.
• The largest YoY upside for Depreciation & Amortization (CF) was 16.08% in 2024 against a maximum downside of 6.5% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $35.4 million in 2022, then gained by 3.67% to $36.7 million in 2023, then grew by 16.08% to $42.6 million in 2024, then increased by 0.23% to $42.7 million in 2025, then changed by 0.0% to $42.7 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $42.7 million (Q2 2026), $40.9 million (Q1 2026), and $42.7 million (Q4 2025), per Business Quant data.